Participants
Eleven PD patients (PD; women n = 5, men n = 6; mean age 65.4 ± 4.5
years, body mass 72.2 ± 12.4 kg, height 168.7 ± 8.9 cm) assessed with
the Hoehn and Yahr scale (H&Y)9 to be mildly
affected, and 11 healthy age-matched controls (HCO; women n = 6, men n =
5; mean age 63.4 ± 4.6 years, body mass 74.1 ±18.9 kg, height 166.4 ±
8.9 cm) participated in our study (Table 1). All PD and HCO subjects
were non-demented (confirmed by a neuropsychologist), right-handed, and
the PD patients had an affected dominant side (Table 1). All subjects
wrote informed consent prior participation in this study which was
approved by the local ethical review board. All study participants
underwent EEG recording, PET/CT neuroimaging and neuropsychological
cognitive assessment, and PD patients underwent additional clinical
neurological evaluation. All PD patients’ testing procedures were
conducted during their “off-medication” phase, i.e. after an overnight
12-hours withdrawal of anti-parkinsonian drugs (24 hours for extended
release medications).